PEDIATRIC ONCOLOGY GROUP

儿科肿瘤组

• 批准号: 3555729
• 负责人: DONALD J FERNBACH
• 金额: $ 21.4万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-01-01 至 1986-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3555729
• 关键词: 6 thiopurine; Hodgkin's disease; child (0-11); combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; daunorubicin; human T cell leukemia; human subject; human therapy evaluation; immunodeficiency; lymphocytic leukemia; methotrexate; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neuroblastoma; pediatric neoplasm /cancer; prednisone; vincristine

The Department of Pediatrics, Baylor College of Medicine, has participated in cooperative cancer study group activities (Southwest Cancer Chemotherapy Study Group, Southwest Oncology Group, Pediatric Oncology Group) for 25 years. The purpose of each group has been to search for better methods of treatment by which to cure or control cancer in children. As a result of these activities, more than half of the children with cancer will survive their disease. In the evolutionary development of these groups, increasing emphasis has been placed upon coordinating multidisciplinary care and on expanding knowledge of cancer biology and pathophysiology. Essential information on the natural history of specific disease entities has provided important knowledge of prognostic factors that are critical elements of modern experimental design. Biostatistical involvement has become an essential part of the integrated programs that now include equal participation by the medical oncology, surgery, pathology, and radiotherapy disciplines. This project will continue this highly successful process.

贝勒医学院儿科系参加了 在合作癌症研究小组活动（西南癌症化疗 研究组，西南肿瘤组，儿科肿瘤组），25 年 每个小组的目的都是寻找更好的方法， 治疗或控制儿童癌症的方法。 的结果 这些活动，一半以上的癌症儿童将生存下来 他们的疾病。 在这些群体的进化发展中， 重点是协调多学科护理， 扩展癌症生物学和病理生理学的知识。 基本 关于特定疾病实体的自然史的信息 提供了重要的预后因素的知识， 现代实验设计的元素。 生物统计学的参与 成为综合计划的重要组成部分，该计划现在包括平等的 肿瘤内科、外科、病理科和放射治疗科的参与 学科 该项目将继续这一非常成功的进程。